Xpert® vanA/vanB
Rapid VRE screening for active outbreak prevention and control in around 48 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
GXVANA/B-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
product image
Collection Device (Pack of 50)
900-0370
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support

The Need

  • Vancomycin Resistant Enterococci (VRE) are a growing public health threat and pose a risk to patient safety in healthcare facilities1
  • In healthcare settings, colonized patients and environmental contamination contribute to VRE spread1
  • High-risk patients colonized with VRE have 24 times the increased infection risk2
  • Infections caused by VRE are associated with high mortality3
  • VRE has an impact on patient length of stay, and in turn, hospitalization costs3
1 Levitus M. et al. Vancomycin-Resistant Enterococci. StatPearls July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK513233/?report=reader#_NBK513233_pubdet. Accessed December 11, 2023
2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016 Dec;4(1):ofw246.
3 Eichel V,M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. Journal of Hospital Infection 141 (2023) 119e128

The Solution

  • The Xpert vanA/vanB test is a rapid and accurate method for detection of VRE colonization among high-risk admissions and for screening during outbreaks of VRE
  • Fast, active screening of high-risk patients to prevent the spread of VRE and better manage colonization in healthcare settings

The Impact

  • The Xpert vanA/vanB test facilitates more efficient infection control surveillance programs:4
    – 93% reduction of turn around time from 70.5h with chromogenic agar culture to 4.6h
    – High negative predictive value allows for better management of non-colonized patients
    – Decreased the number of contact patients thereby preventing VRE transmission
    – 94% reduction in overall cost (€14,302 with culture vs €870)
  • Compared to culture, faster time to result may support more effective patient management: more isolation and transmission risk days saved5
    – 141 saved isolation days and 292 saved transmission risk days
4 Birgand G, et al. Lucet JC. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrobial Resistant and Infection Control.
2013 Nov ; 2:30.
5 Holzknecht BJ, Hansen DS, Nielsen L, Kailow A, Jarløv JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on
infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59